There has been a low uptake of the new (available since early September ’22) bivalent booster COVID-19 vaccine in the USA (~15% of the population as of 10th January 2023). In this work, we set to ask the reasons why people are, or are not, electing to take the bivalent booster. One key finding from analyzing survey data is that many people did not know about the new bivalent booster, or did not know they were eligible — suggesting more public health communication is necessary to promote uptake of the new vaccines. You can read more about it here.
In early 2020, members of the Weitz Group were part of a dedicated team of Georgia Tech researchers, engineers, campus leaders, and staff members working to establish Georgia Tech’s surveillance testing program. The goal of the program was to use testing to reduce the spread of Covid-19 and increase campus safety.
A collaborative paper on the effectiveness of the surveillance testing program is out now in Epidemiology. In addition to Prof. Weitz, research scientist Stephen Beckett, Ph.D., collaborative group member Conan Zhao, and former member Ashley Coenen, Ph.D. were involved in the project.
Read more about the paper in an article published by the Georgia Tech Research News.
Photo credit: Allison Carter.
Photo credit: Tara Clemente.